autism riskfactor cardiovascular disease and diabetes
Conditions
Interventions
None listed
Sponsors
GGZ Centraal (Amersfoort)
Eligibility
Age
2 Years to 17 Years
Inclusion criteria
Inclusion criteria: Paediatric patients aged between 6 and 18 years with a DSM- IV-TR diagnosis of ASD with and without an indication for treatment with antipsychotic medication. Co-medication like stimulants or SSRI*s is allowed. Patients on antipsychotic medication will start with this medication and have to be antipsychotic-naïve.
Exclusion criteria
Exclusion criteria: • History of treatment with antipsychotic medication (ASD group without antipsychotic medication) • Treatment with more than 1 SGA • Active or past eating disorder • Biochemical evidence of thyroid dysfunction/diabetes mellitus. • Pregnancy or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Insulin resistance (HOMA2-IR) | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting glucose, HbA1c Fasting trygliceriden HDL, LDL en total cholesterol Insulin Prolactin Testosteron (boys) Oestradiol (girls) Weight Height BMI and BMI z-score Fat percentage Bloodpressure and heart rate Haircortisol Effectscales • Aberrant Behavior Checklist Irritability subscale (Aman 1985) • Clinical Global Impression improvement scale (Guy, 1976) • Social responsiveness scale (Constantino, 2003) • Repetitive behaviour Scale-R (Lam 2007) Pubertal stage (Tanner) Questionnaire of fysical activity/eating behaviour Level of activity measured bij an actigraph (GENEActiv®) Ethnicity (country of birth both parents) Socio-economic status (Education level both parents) Weight status of both parents (BMI). | — |
Countries
Netherlands
Outcome results
None listed